VP & Chief Medical Officer, Medtronic Structural Heart. Cardiovascular Surgeon - Professor of Surgery & Medicine
Atlanta, GA
- Tweets 506
- Following 269
- Followers 2,919
- Likes 1,214
Pinned Tweet
4 Heart Surgeons walked into a bar -Bartender served the 1st and asked, “What will you have?”
“I’ll have what she’s having.”
Women of Emory Cardiac Surgery.
Dr. Amalia Jonsson-Robotic Surgeon
Dr. Subhadra Shashidharan-Congenital Surgeon
Dr. Alison Ward-Adult Surgeon
And Me
51
72
1,922
Kendra J. Grubb MD, MHA, MSc retweeted
At the @Medtronic-sponsored lunch symposium at RISE @ ESC Congress 2026, the message was clear: equity in CV care and careers must move faster.
Practical solutions, from community BP checks to intentional sponsorship, can help women lead & access care.
#LetsRISE26 #ESCCongress
2
10
535
Kendra J. Grubb MD, MHA, MSc retweeted
Late-breaking real-world evidence at #CRT2026:
Linking registry + Medicare claims offers one of the clearest looks yet at long-term TAVR durability in low-risk patients.
Highlights:
• 12,684 low-risk patients
• Reintervention remained low across generations
• ~2–3% at 5–6 years overall
• Mortality remained substantial, reflecting real-world aging/comorbidity burden
A valuable look at durability beyond trial populations.
Great work by @rwyeh and team!
#TAVR #StructuralHeart #CardioX @crt_meeting @ron_waksman @GreggWStone @TheDoctorMack @KarenMKimMD1 @PopmaJeffrey @MReardon19 @SachinGoelMD
2
6
24
3,236
Kendra J. Grubb MD, MHA, MSc retweeted
Ex-vivo study of 23 to 34 mm Evolut THVs: IFU-guided post-dilation preserved frame geometry and leaflet integrity. Oversized balloons caused waist over-expansion and immediate leaflet tears. jacc.org/doi/10.1016/j.jcin.… #JACCINT
17
54
5,885
Evolut Low Risk Trial JACC Publication: lnkd.in/gWz6Vh6S
Postdilation of Evolut Transcatheter Heart Valves: Insights for Bench Testing (JACC Interventions): lnkd.in/g479azbG
7
855
Kendra J. Grubb MD, MHA, MSc retweeted
In this #JACCINT state-of-the-art review, read about choosing the right alternative access for #TAVR, balancing feasibility, safety & efficacy. jacc.org/doi/10.1016/j.jcin.…
#CardioX @thiele_holger @fjsawaya @KendraGrubb @Mo_A_W
33
102
16,202
Kendra J. Grubb MD, MHA, MSc retweeted
Early outcomes following 151 #TAVR implants with the new Evolut FX self-expanding valve, as reported in the Optimize PRO FX Addendum study, demonstrate the lowest published 30-day #PPI rate (6.7%) from #Evolut platforms. jacc.org/doi/10.1016/j.jcin.… #JACCINT
1
3
24
4,307
Kendra J. Grubb MD, MHA, MSc retweeted
In our latest webcast, JoAnn Lindenfeld, @spinneymd, and @KendraGrubb discuss the impact of transcatheter mitral valve replacement for heart failure patients as well as the current barriers to treatment. tctmd.com/TMVR-in-the-Heart-…
1
4
691
Kendra J. Grubb MD, MHA, MSc retweeted
🌐 Today’s industry panel explored how companies can champion gender equity in cardiology on both regional and global scales.
A powerful discussion on collaboration, accountability, and creating lasting impact for women in medicine.
#LetsRISE2025
1
6
20
1,037
Kendra J. Grubb MD, MHA, MSc retweeted
Watch @KendraGrubb, @GilbertTangMD, and Firas Zahr take a deep dive into the 2-year transfemoral EFS outcomes for the Intrepid TMVR system presented at NY Valves 2025. tctmd.com/Insights-on-Intrep…
1
3
8
1,510
Kendra J. Grubb MD, MHA, MSc retweeted
On this episode of Talking Points, @KendraGrubb, Tim Byrne, and Hussam Suradi discuss the importance of patient selection for transcatheter interventions and defining treatment goals at #NYValves2025. tctmd.com/audio/patient-sele…
2
2
784
Kendra J. Grubb MD, MHA, MSc retweeted
On this episode of Talking Points, @KendraGrubb, @hahn_rt, and @dralisonduncan discuss ways to improve trial integrity, operational efficiency, and regulatory approval of transcatheter devices. tctmd.com/audio/echocardiogr…
1
1
665
Kendra J. Grubb MD, MHA, MSc retweeted
The Intrepid TMVR system just released 2-year transfemoral EFS outcomes at #NYValves2025, featuring @KendraGrubb, @GilbertTangMD, & Firas Zahr. Listen to this Talking Points episode for more on what this data means for the Intrepid mitral program: tctmd.com/audio/insights-int…
3
4
1,176
Kendra J. Grubb MD, MHA, MSc retweeted
Join us at RISE @ ESC Congress 2025 for a lunch symposium on women’s heart health.
🎤 Expert panel: Drs. @mirvatalasnag, @KendraGrubb, @PamTaubMD & Joanna Wykrzykowska
📣 A global call to action
Register: rise.womenasone.org
#LetsRISE2025 #ESCCongress #WCCardio #WIC
ALT Text reads: Championing Women’s Heart Health: A Call to Action. August 28, RISE @ ESC Congress 2025, Madrid, Spain. Sponsored by Medtronic.
2
7
19
2,621
Kendra J. Grubb MD, MHA, MSc retweeted
“I had the audacity to ask, ‘Why have you never trained a woman?’—then volunteered to be the first.” – Dr. @KendraGrubb
Hear her journey in endovascular medicine, #TAVR innovation, and the power of mentorship.
🎧livinglegendsandluminaries.b…
2
8
861
Kendra J. Grubb MD, MHA, MSc retweeted
💡The Optimize PRO study, conducted in 50 centers worldwide (653 pts), reported a 30day primary endpoint of 5.1% for all-cause mortality or #stroke & a new low permanent pacemaker implantation rate (6.4%, 4-step COT) after #TAVR w Evolut PRO/PRO+. Read more⬇️
➡️doi.org/10.1016/j.jscai.2025…
@KendraGrubb @HemalGada @tnazifMD @DvirDanny @JoshuaRovin @ramzik1971 @ChetcutiStan @StevenYakubov @dmylotte @PaulMahoneyMD
2
3
832
Kendra J. Grubb MD, MHA, MSc retweeted
Follow the 2025 conversations with #ThePulse
Episode 1️⃣ @KendraGrubb with @AymanAlSaleh @RHAAttar
👉 piped.video/aSwKVTJlCxY?feature…
9
27
8,086
Kendra J. Grubb MD, MHA, MSc retweeted
Kudos Dr. @KendraGrubb for Impact of Transcatheter or Surgical Aortic Valve Performance on 5-Year Outcomes in Patients at ≥ Intermediate Risk."
tinyurl.com/7nykbn7w
@EmoryCTSRes @EmorySurgery @EmoryCTSurgery @EmoryMedicine @emoryhealthcare
1
270
Kendra J. Grubb MD, MHA, MSc retweeted
An opportunity to meet influential researchers, society leaders & industry CMOs
@Drroxmehran @alaide_chief @KendraGrubb @dr_nouf81 @Rasha_Alfawaz @LemmeseAlwatban @ada_mq @HindAlosaimi_ @SSamargandy @DrShereen_ @RashaKaddoura2 @ZainabDakhil2 @rashaalbawardy @FaiezZANNAD @baileyannRN @AlrahimiJ @halbackr @biljana_parapid
✨ Only at #TCTMiddleEast2025! Join us for an extraordinary evening dedicated to shaping the future of women’s cardiovascular research!
Under the patronage of Her Royal Highness Princess Haifa Al-Faisal bin Abdulaziz Al Saud, this special session brings together global leaders and changemakers to drive progress in women’s heart health.
🗓️ Thursday, 17 April | 🕢 19:30 – 22:30 | 📍 Riyadh Main Arena
Be part of this game-changing conversation and help drive innovation in women’s cardiovascular care! tctmiddleeast2025.crfconfere…
🔗 Not registered yet? Reserve your spot now! tctmiddleeast2025.crfconfere…
#CardioX #CardioTwitter #CardioEd #CardioResearch @jgranadacrf @triciarawh @TCTConference @mirvatalasnag @kfaraidy @drptca @mmamas1973 @AlkashkariWail @TCT_ME_
18
28
6,624
Kendra J. Grubb MD, MHA, MSc retweeted
Finally out @JACCJournals 5y BVD in CoreValve/Evolut #TAVR vs SAVR. ⬇️BVD SVD NSVD (PPM) in #TAVR. BVD ⬆️☠️. Bottom line: Any AVR avoid BVD! We can control NSVD (PVL, PPM) but SVD harder to predict. Operators should optimize index #TAVR when feasible and safe in all pts. @MDT_StructHeart Congrats my friend @StevenYakubov @drnvanmieghem @KendraGrubb et al on this important paper!
#CRT2025 #JACC SimPub: 5-year valve performance is significantly better after CoreValve/Evolut #TAVI compared to surgery. The development of BVD in TAVI and surgery patients was associated with worsened 5-year clinical outcomes. jacc.org/doi/10.1016/j.jacc.… #cvSurg
13
58
14,766